IDT Biologika appoints Federico Pollano as new Chief Commercial Officer
Federico Pollano is new Chief Commercial Officer (CCO) at IDT Biologika
IDT Biologika, a leading global contract development and manufacturing organization (CDMO) for end-to-end services in the development and production of viral vaccines, gene and immunotherapeutics and filling of sterile injectables, appoints Federico Pollano as Chief Commercial Officer effective March 1, 2025.
Federico Pollano has extensive experience in management positions at global CDMOs in the pharmaceutical and biotechnology industry. Prior to joining IDT Biologika he was Senior Vice President Business Development at Rentschler Biopharma for the past seven years. During this period, he assumed responsibility for sales management and customer service. He also joined the Extended Executive Board in 2023. Before taking on this role, Federico Pollano built up the CDMO business as Global Director Contract Manufacturing and Business Development at Polpharma Biologics and was Managing Director at Richter-Helm-BioTec and Executive Manager Pharmaceuticals at Helm Pharmaceuticals. After studying biology, clinical research, health economics and the licensing business as well as M&A projects were important stations at GSK and Ratiopharm.
“I am very much looking forward to my new role at IDT Biologika and especially to contributing my skills and dedication to this great team. IDT has already established itself as a reliable partner in the market and is currently experiencing growth alongside SK bioscience. I am excited about contributing to this growth, particularly by strengthening and expanding relationships with customers and leveraging the full range of IDT’s capabilities to ensure the success of our clients’ projects,” says Federico Pollano
“In Federico Pollano, we have found an outstanding personality for this position, both personally and professionally. We want to strengthen our global network and strategically expand our business, and Federico Pollano’s many years of experience in the CDMO business will provide us with important inspiration,” adds Dr. Sally Choe, Co-CEO IDT Biologika.
